Table 1 Demographics, cyst morphological features, and PCF analysis
From: Endoscopic ultrasound with fine needle aspiration is useful in pancreatic cysts smaller than 3 cm
Patients, n | 115 |
Females, n (%) | 75 (65%) |
Mean age, years | |
Mean ± standard deviation (range) | 63 ± 12 (33–86) |
F-up time, months | |
Mean ± standard deviation (range) | 37 ± 30 (6–134) |
Symptoms, n (%) | 21 (18.3%) |
Cysts, n | 115 |
Location n, (%) | |
Head | 45 (39.1%) |
Body | 42 (36.6%) |
Tail | 23 (20%) |
Multiple | 5 (4.3%) |
Size, mm | |
Mean ± standard deviation (range) | 19 ± 6 (5–29) |
Size, n (%) | |
≤ 10 mm | 10 (8.7%) |
10–20 mm | 56 (48.7%) |
≥ 20 mm | 49 (42.6%) |
Mural nodule/mass, n (%) | 31 (27%) |
Mural nodule/mass, size (mm) | |
Mean ± standard deviation (range) | 16.2 ± 12.2 (2–49) |
Size > 10 mm, n (%)a | 13 (52%) |
Wirsung dilation, n (%) | 0 (0%) |
PCF analysis | |
CEA, n (%)b | |
≤ 5 ng/mL | 18 (18.2%) |
5–192 ng/mL | 42 (42.4%) |
≥ 192 ng/mL | 39 (39.4%) |
Amylase, n (%)c | |
< 250 UI/mL | 38 (39.6%) |
≥ 250 UI/mL | 50 (60.4%) |
Cytology | |
Acellular | 75 (65.2%) |
Benign or inflammatory | 20 (17.4%) |
LGD | 3 (2.6%) |
Malignant, atypical, NET | 17 (14.8%) |
Clinical decision after EUS-FNA, n (%) | |
Surgery | 19 (16.5%) |
Imaging surveillance | 80 (69.6%) |
Palliationd | 5 (4.3%) |
Lost to follow-up | 11(9.6%) |